Landos Biopharma, Inc. (LABP) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	S-1/A
Revenues [+]	0.0	18.0	0.0	11.8	6.8
Royalties				11.8	6.8
Revenue growth	-100.0%		-100.0%	73.6%
Cost of goods sold	0.0	0.0	0.0	13.3	7.9
Gross profit	0.0	18.0	0.0	-1.5	-1.1
Gross margin		100.0%		-12.5%	-16.7%
Selling, general and administrative [+]	40.6	56.8	30.7	1.5	1.1
General and administrative				1.5	1.1
Other operating expenses	-40.6			10.3	5.7
EBITDA [+]	0.6	-38.6	-30.5	-13.2	-7.9
EBITDA growth	-101.5%	26.5%	131.6%	67.8%
EBITDA margin		-214.6%		-111.6%	-115.5%
Depreciation and amortization	0.6	0.2	0.1	0.1	0.1
EBIT [+]	0.0	-38.8	-30.7	-13.3	-7.9
EBIT growth	-100.0%	26.5%	130.8%	67.4%
EBIT margin		-215.6%		-112.5%	-116.7%
Interest expense				0.3
Interest expense				0.3
Other income (expense), net [+]	-39.3	0.4	0.5	0.1	1.9
Other				-0.2	1.9
Pre-tax income	-39.3	-38.4	-30.1	-13.5	-6.0
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-39.3	-38.4	-30.1	-13.5	-6.0
Net margin		-213.5%		-114.0%	-88.8%

Basic EPS [+]	($0.98)	($1.02)	($2.47)	($1.18)	($0.59)
Growth	-4.6%	-58.5%	108.6%	101.2%
Diluted EPS [+]	($0.98)	($1.02)	($2.47)	($1.18)	($0.59)
Growth	-4.6%	-58.5%	108.6%	101.2%

Shares outstanding (basic) [+]	40.3	37.6	12.2	11.4	10.3
Growth	7.2%	207.2%	7.3%	10.7%
Shares outstanding (diluted) [+]	40.3	37.6	12.2	11.4	10.3
Growth	7.2%	207.2%	7.3%	10.7%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.